Trials Sponsors Conditions Drugs Pricing

Conditions

Multiple Myeloma Renal Failure

Keywords

Multiple MyelomaRenal FailureAutologous Hematopoietic Stem Cell Transplantation (ASCT)Melphalan

Outcome Measures

Primary Outcomes (1)

Non Relapse Mortality post-transplantation
Non-relapse mortality at Day +100 post-transplantation will be reported.
100 days post-transplantation

Secondary Outcomes (5)

Overall survival
2 years post-transplantation
progression-free survival
2 years post-transplantation
Number of toxicities
2 years post-transplantation
presence of hematological response
6 months
Level of renal response
3 months, 6 months and one year

Study Arms (1)

Myeloma patients with severe renal impairment

Myeloma patients with severe renal impairment. Data collection will concern myeloma patients with severe renal impairment who are susceptible to undergo autologous transplantation.

Other: Data collection

Interventions

Data collectionOther

Myeloma patients with severe renal impairment who are susceptible to undergo autologous transplantation will be followed in this study, and data related to the pathology, treatments and transplantation will be reported.

Myeloma patients with severe renal impairment

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age66 Years+

Sexall

Healthy VolunteersNo

Age GroupsOlder Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Myeloma patients with severe renal impairment suseptible of undergoing autologous transplantation.

You may qualify if:

Age ≤ 66 years-old

Sponsors & Collaborators

Centre Hospitalier Universitaire de Saint Etienne
Otherlead
Institut de Cancérologie de la Loire
Othercollaborator

Study Sites (33)

Centre Pierre et Marie Curie

Algiers, Algeria

EHU Oran

Oran, Algeria

CHU Sart Tilman

Liège, Belgium

Centre Hospitalier Universitaire d'Amiens

Amiens, France

Centre Hospitalier Universitaire d'Angers

Angers, 49933, France

Centre Hospitalier d'Argenteuil

Argenteuil, 95100, France

Centre Hospitalier de la Côte Basque

Bayonne, France

MeSH Terms

Conditions

Multiple MyelomaRenal Insufficiency

Interventions

Data Collection

Condition Hierarchy (Ancestors)

Neoplasms, Plasma CellNeoplasms by Histologic TypeNeoplasmsHemostatic DisordersVascular DiseasesCardiovascular DiseasesParaproteinemiasBlood Protein DisordersHematologic DiseasesHemic and Lymphatic DiseasesHemorrhagic Disorders

Study Officials

Jérôme Cornillon, MD
CHU de Saint-Etienne
PRINCIPAL INVESTIGATOR

Enrollment

50 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Target Duration: 2 Years
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

July 26, 2017

First Posted

July 31, 2017

Study Start

April 10, 2018

Actual (reported)

High Dose Therapy Followed by Autologous Transplantation for Myeloma Patients With Severe Renal Impairment

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (5)

Study Arms (1)

Myeloma patients with severe renal impairment

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (33)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (5)

Study Arms (1)

Myeloma patients with severe renal impairment

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (33)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Source record

Locations